Article

Optimization and Characterization of a Tofacitinib Citrate-Loaded Dermal Nanoemulgel for Rheumatoid Arthritis

Sayani Bhattacharyya1★, Raman Dang2, Nikhath Fathima Muheeb1, Sushma Ramanna1, Kogileshwari Sivakumar1★ Corresponding author

  1. 1Department of Pharmaceutics, Krupanidhi College of Pharmacy, Bengaluru, Karnataka, INDIA.
  2. 2Department of Pharmacognosy, Krupanidhi College of Pharmacy, Bengaluru, Karnataka, INDIA.

CORRESPONDENCE

Sayani Bhattacharyya

Department of Pharmaceutics, Krupanidhi College of Pharmacy, Bengaluru, Karnataka, INDIA.

sayanibh@gmail.com

Received: 18-04-2026; Revised: 03-06-2026; Accepted: 27-08-2026.

Volume 60, Issue 4S · pp. s1795–s1806 · PUBLISHED 2026 · DOI: 10.5530/ijper.20265544

View on IJPER original site ↗

ABSTRACT

Aim: Rheumatoid Arthritis (RA) is a progressive autoimmune disorder characterized by joint inflammation and functional disability. Conventional oral therapy with tofacitinib citrate exhibits poor bioavailability as it undergoes extensive hepatic metabolism, and is associated with systemic adverse effects. The present research proposes a novel topical nanoemulgel formulation of tofacitinib to overcome the drawbacks of conventional therapy. Materials and Methods: Nanoemulsion was prepared with eucalyptus oil, tween 20, and labrafil M2125. A statistical design was employed to optimize drug loading and particle size. The optimized nanoemulsion was incorporated into a Carbopol 934 gel base and evaluated for physicochemical properties, rheology, spreadability, ex vivo permeation, and in vivo antiarthritic activity. Results: The optimized nanoemulsion exhibited a mean particle size of 180 nm, drug loading of ~71%. Surface morphology by TEM confirmed formation of stable nanosized vesicles. The nanoemulgel exhibited favourable viscosity, pH, spreadability, and sustained release profile. Ex vivo studies confirmed enhanced permeation compared to pure drug gel. In vivo results demonstrated reduced paw edema, improved mobility, and near-normal histological architecture. Conclusion: Therefore, nanoemulagel of tofacitinib citrate can be a promising alternative to oral therapy in RA management.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Bhattacharyya, S., Dang, R., Muheeb, N. F., Ramanna, S., & Sivakumar, K. (2026). Optimization and Characterization of a Tofacitinib Citrate-Loaded Dermal Nanoemulgel for Rheumatoid Arthritis. Indian Journal of Pharmaceutical Education and Research, 60(4S), s1795–s1806. https://doi.org/10.5530/ijper.20265544